Page 2 - Anthony Windebank News Today

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease. The deadly neurological disease has few treatment options. NurOwn, a stem cell therapy, is at the center of a yearslong lobbying campaign by patients seeking access to experimental medicines. But the FDA has repeatedly rebuffed drugmaker Brainstorm. The agency says the company's only study failed to show a benefit for patients. The review is the starkest test yet of FDA's c...

“FDA is the 800-pound gorilla here, and if they’re convinced that the drug doesn’t work, it’s very hard to change their minds,” a former FDA official said.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.

The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.

In documents posted Monday, the FDA reiterated its longstanding position that drugmaker Brainstorms lone study doesnt provide convincing evidence that its stem cell-based therapy helps patients with ALS, or amyotrophic lateral sclerosis.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.

The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.